World Pain Relieving Drug Market 2013-2023

PR Newswire

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Pain Relieving Drug Market 2013-2023

http://www.reportlinker.com/p0572964/World-Pain-Relieving-Drug-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

New study reveals sales potential of this large, expanding market

See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You see why the pain relievers industry and market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 84 tables, 79 charts and three research interviews.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of five world-level submarkets to 2023:

  • Narcotics
  • Non-narcotics
  • Neuropathic pain relievers
  • Treatments for migraines
  • Treatments for arthritis.

Also, you see how 29 leading drugs - including Oxycontin ER, Panadol, Lyrica and Zomig - can perform to 2023. Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. There, you find revenue forecasts and other data.

The work also breaks the overall world market into leading national markets.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

You discover revenue forecasts to 2023 for twelve national markets:

  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5 nations)
  • India
  • China
  • Brazil
  • Russia
  • Turkey

This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D pipeline for painkillers? You see developmental trends there:
  • Narcotic drugs
  • Non-narcotic products
  • Neuropathic treatments
  • Anti-migraine agents
  • Arthritic pain relievers.

Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the pain treatment sector

Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:

  • Better treatment of acute and chronic pain worldwide, including cancer pain
  • Anticonvulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
  • Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
  • Disease modifying anti-rheumatic drugs (DMARDs)
  • Biologics (e.g. monoclonal antibodies, MAbs) for rheumatoid arthritis (RA)
  • Reimbursement, regulations, patent expiries, generic competition and OTC switching.

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues there from 2013 to 2023. The R&D pipeline is strong.

Overall world revenue for that market area will reach $68.0bn in 2013, our report forecasts. Ageing populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.

Eight ways World Pain Relieving Drug Market 2013-2023 benefits you

In particular, then, our study gives you the following knowledge on painkilling drugs:
  • Forecasted revenues to 2023 for the overall world market and submarkets
  • Potential revenues of 29 leading products to 2023
  • Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil, Russia and Turkey
  • Assessment of companies - discussions of activities and outlooks
  • Review of R&D pipelines by treatment area - progress and trends
  • Opinions on the sector, including our research interviews with leaders in industry
  • Investigation of competition and opportunities influencing sales
  • Discussion of what stimulates and restrains the industry and market.

That work gives independent analyses from our primary and secondary research. You receive information found only in our report.

With our study, you find business intelligence to help you understand the future of that industry and market.

Ordering now lets you discover prospects for drugs treating pain

Visiongain's study is for everybody needing commercial analyses for the treatment of pain. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary1.1 The Pain Relieving Drug Market: Overview

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to the Pain Relieving Drug Market

2.1 What is Pain?

2.1.1 Historical Aspects of Pain

2.2 Pain Pathways and the Origin of Pain

2.2.1 WHO Pain Ladder

2.3 Classification and Types of Pain

2.3.1 Acute Pain

2.3.2 Chronic Pain

2.3.3 Psychosocial Effects of Chronic Pain

2.3.4 Chronic Cancer Pain

2.3.5 Breakthrough Cancer Pain

2.4 Neuropathic Pain

2.4.1 Distinguishing Neuropathic Pain

2.5 Neurochemistry of Pain

2.5.1 Prostaglandins

2.5.2 Opioids

2.6 Treatment

2.6.1 Opioids in the Treatment of Pain

2.7 OTC Pain Relievers

3. The World Pain Relieving Drug Market, 2013-2023

3.1 The World Pain Relieving Drug Market: Analysis and Forecast, 2013-2023

3.2 Submarket Categories of the World Pain Drug Market

3.2.1 Anti-Arthritic Drug Sales Will Continue to Dominate

3.2.2 Neuropathic Pain Market Will Grow

3.3 Success in the World Pain Treatment Market Has Been Challenging

3.4 The Pain Relieving Drug Market Will Expand

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast, 2013-2023

4.1 Oxycontin ER (Purdue Pharma): Market Analysis and Forecast, 2013-2023

4.1.1 Launch of Tamper Resistant Oxycontin ER4.1.2 Patent and Legal Battles of Oxycontin ER

4.1.3 Oxycontin ER Sales Forecast, 2013-2023

4.2 Opana ER (Endo Pharmaceuticals): Market Analysis and Forecast, 2013-2023

4.2.1 Development of Tamper Resistant Opana ER

4.2.2 Opana ER Sales Forecast, 2013-2023

4.3 Duragesic (Johnson & Johnson): Market Analysis and Forecast, 2013-2023

4.3.1 Duragesic Sales Forecast, 2013-2023

4.4 Ultram (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2013-2023

4.5 Zaldiar/Ultracet (Grunenthal): Market Analysis and Forecast, 2013-2023

4.6 World Market Forecast for Other Narcotic Drugs, 2013-2023

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast, 2013-2023

5.1 Advil (Pfizer): Market Analysis and Forecast, 2013-2023

5.1.1 Development of Advil (Ibuprofen)

5.1.2 Advil Sales Forecast, 2013-2023

5.2 Panadol (GSK): Market Analysis and Forecast, 2013-2023

5.2.1 Panadol Sales Forecast, 2013-2023

5.3 Bayer Aspirin (Bayer): Market Analysis and Forecast, 2013-2023

5.3.1 Development of Bayer Aspirin (Acetylsalicyclic Acid)

5.3.2 Bayer Aspirin Sales Forecast, 2013-2023

5.4 Efferalgan (Bristol-Myers Squibb): Market Analysis and Forecast, 2013-2023

5.5 Tylenol (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2013-2023

5.5.1 Eroded Sales in 2012

5.5.2 Tylenol Sales Forecast, 2013-2023

5.6 Other Non-Narcotic Pain Relieving Drugs: Market Analysis and Forecast, 2013-2023

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast, 2013-2023

6.1 Treatment Options

6.2 Pharmacological Treatments

6.2.1 Anti-Convulsants

6.2.2 Analgesics

6.2.3 Local Anaesthetics

6.2.4 Anti-Depressants

6.2.5 Aldose Reductase Inhibitors

6.3 World Neuropathic Pain Relieving Drug Sales Forecast, 2013-2023

6.4 Lyrica (Pfizer): Market Analysis and Forecast, 2013-2023

6.4.1 Impact of Lyrica Patent Expiry

6.5 Cymbalta (Eli Lilly): Market Analysis and Forecast, 2013-2023

6.6 Lidoderm (Endo Pharmaceuticals): World Market Analysis and Forecast, 2013-2023

6.6.1 Impact of Lidoderm Patent Expiry

6.7 Neurontin Market Forecast, 2013-2023

6.8 Nucynta Franchise (Grunenthal GmbH, Johnson & Johnson): Market Analysis and Forecast, 2013-2023

6.8.1 Development of Nucynta ER (Tapentadol)

6.8.2 Nucynta Franchise Sales Forecast, 2013-2023

6.8.3 Nucynta Franchise Has High Potential

6.9 Qutenza (NeurogesX) and NGX-1998 Market Prospects

6.10 Kinedak (Ono Pharmaceuticals) Market Prospects

6.11 Development and Market Prospects of Horizant (Xenoport, GSK)

6.12 Will Gralise (Depomed) Become a Market Leader?

6.13 Future Treatment of Neuropathies

6.13.1 Therapies That Can Target the Underlying Cause Are in Demand

7. Anti-Migraine Drugs: World Market Analysis and Forecast, 2013- 2023

7.1 How is Migraine Treated and Prevented?

7.1.1 Migraine Treatment

7.1.2 Migraine Prevention

7.2 World Anti-Migraine Drug Sales Forecast, 2013-2023

7.3 Maxalt (Merck & Co.): Market Analysis and Forecast, 2013-2023

7.4 Zomig (AstraZeneca): Market Analysis and Forecast, 2013-2023

7.5 Relpax (Pfizer): Market Analysis and Forecast, 2013-2023

7.6 Imitrex/Imigran (GSK): Market Analysis and Forecast, 2013-2023

7.7 Botox (Allergan): Market Analysis and Forecast, 2013-2023

7.7.1 Botox Will Boost World Migraine Sales

7.8 Axert (Johnson & Johnson, Almirall): Market Analysis and Forecast, 2013-2023

7.9 Treximet (GSK, Pozen): Market Analysis and Forecast, 2013-2023

7.10 What Does the Future Hold for Migraine Therapy?

7.11 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast, 2013-2023

8.1 Arthritis

8.2 What Drugs are used to Treat Arthritis?

8.2.1 Pain Relieving Drugs and Analgesics

8.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

8.2.3 Corticosteroids

8.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)

8.2.5 Biologics

8.3 Biologics for Rheumatoid Arthritis Treatment

8.3.1 Side Effects of Biologics

8.4 World Anti-Arthritic Pain Drug Sales Forecast, 2013-2023

8.5 Humira (Abbott Laboratories): Market Analysis and Forecast, 2013-2023

8.5.1 Long-Term Prospects for Humira

8.6 Enbrel (Amgen, Pfizer, Takeda): Market Analysis and Forecast, 2013-2023

8.6.1 Amgen Continues to Benefit from Enbrel Sales

8.6.2 Enbrel Sales Will Show an Initial Increase

8.6.3 Study Eases Fears of TNF Blocker Cancer Risk

8.6.4 New Enbrel Delivery System

8.6.5 Sales of Enbrel will Eventually Decline

8.6.6 Enbrel Faces Competition from Several Other Biotech Drugs

8.7 Remicade (Johnson & Johnson): Market Analysis and Forecast, 2013-2023

8.7.1 Long Term Prospects for Remicade

8.8 Rituxan (MabThera-Roche; Biogen Idec): Market Analysis and Forecast, 2013-2023

8.8.1 Rituxan is a Leading Biosimilar Target

8.9 Celebrex (Pfizer): Market Analysis and Forecast, 2013-2023

8.9.1 Development of Celebrex

8.9.2 Celebrex Sales Forecast, 2013-2023

8.10 Voltaren (Endo, Novartis): Market Analysis and Forecast, 2013-2023

8.10.1 Voltaren Sales Forecast, 2013-2023

8.11 Arcoxia (Merck & Co.): Market Analysis and Forecast, 2013-2023

8.11.1 Development of Arcoxia

8.11.2 Arcoxia Sales Forecast, 2013-2023

8.12 Outlook for the Anti-Arthritic Pain Drug Market

9. Leading National Markets for Pain Relieving Drugs, 2013-2023

9.1 The Pain Relieving Drug Market: Regional Sales Breakdown

9.2 Pain Drug Revenues in Leading National Markets, 2013-2023

9.2.1 The Pain Relieving Drug Market in the US, 2013-2023

9.2.2 The Pain Relieving Drug Market in Japan, 2013-2023

9.2.3 Top 5 EU Markets for Pain Relieving Drugs, 2013-2023

9.2.4 The Pain Relieving Drug Market in Germany, 2013-2023

9.2.5 The Pain Relieving Drug Market in France, 2013-2023

9.2.6 The Pain Relieving Drug Market in the UK, 2013-2023

9.2.7 The Pain Relieving Drug Market in Italy, 2013-2023

9.2.8 The Pain Relieving Drug Market in Spain, 2013-2023

9.3 Emerging Economies Showing Strong Performance, 2013-2023

9.3.1 The Pain Relieving Drug Market in China, 2013-2023

9.3.2 The Pain Relieving Drug Market in Brazil, 2013-2023

9.3.3 The Pain Relieving Drug Market in Russia, 2013-2023

9.3.4 The Pain Relieving Drug Market in India, 2013-2023

9.3.5 The Pain Relieving Drug Market in Turkey, 2013-2023

9.4 The Pain Relieving Drug Market in the Rest of the World, 2013-2023

10. The R&D Pipeline for the Treatment of Pain, 2013

10.1 The R&D Pipeline for Pain Drugs is Large and Expanding

10.2 The Potential of the Pain Market Has Encouraged R&D

10.3 Innovation Rules for Early Stage Pipeline Drugs

10.4 Narcotic Pain Relieving Drug Pipeline, 2013

10.4.1 Acurox (Acura, Pfizer)

10.4.2 Remoxy (Pfizer, Pain Therapeutics, Durect)

10.4.3 BEMA Buprenorphine (BioDelivery Sciences, Endo Pharmaceuticals)

10.4.4 Morphine Glucuronide (Paion)

10.4.5 MoxDuo IR (Shire; China Aoxing; QRxPharma)

10.4.6 Acuracet (Pfizer, Acura)

10.4.7 ARX 02 (AcelRx Pharmaceuticals)

10.4.8 Zohydro ER (Zogenix)

10.4.9 COL-003 (Collegium)

10.4.10 ALO 02 (Pfizer)

10.4.11 Subsys (Insys Therapeutics)

10.4.12 Oxceta (Pfizer, Acura)

10.5 Non-Narcotic Pain Relieving Drug Pipeline, 2013

10.5.1 Exparel (Pacira Pharmaceuticals)

10.5.2 Lofexidine HCl (US WorldMeds)

10.5.3 Synera (Nuvo Research)

10.5.4 Neosaxitoxin (Proteus SA)

10.5.5 Adlea (ALRGX-4975) (Anesiva, Johns Hopkins University)

10.5.6 OMS 103 HP (Omeros)

10.5.7 Tetrodotoxin (WEX, CK Life Sciences)

10.5.8 CE 224535 (Pfizer)

10.5.9 MK-2295 (Ligand, Merck & Co.)

10.6 Neuropathic Pain Relieving Drug Pipeline, 2013

10.6.1 Retigabine (Valeant, GSK)

10.6.2 Perampanel (Eisai)

10.6.3 Serenbotase (Syntaxin, Allergan)

10.6.4 EMA401 (Spinifex)

10.6.5 KRN5500 (Dara Biosciences)

10.6.6 NT-11624 (Neurotune)

10.6.7 ARC-2022 (Arcion)

10.6.8 ARC-4558 (Arcion)

10.6.9 Amiket (EpiCept)

10.6.10 Ralfinamide (Newron)

10.6.11 Eladur (Durect)

10.6.12 AVP-923 (Avanir Pharmaceuticals)

10.7 Anti-Migraine Drug Pipeline, 2013

10.7.1 Zelrix (NuPathe)

10.7.2 BMS-927711 (Bristol-Myers Squibb)

10.7.3 Lasmiditan (CoLucid Pharmaceuticals)

10.7.4 Telcagepant (Merck & Co.)10.7.5 NXN-188 (NeurAxon)

10.7.6 BGG492 (Novartis)

10.7.7 LY2300559 (Eli Lilly)

10.8 Anti-Arthritic Pain Drug Pipeline, 2013

10.8.1 Duexa (Horizon Pharma)

10.8.2 Zavryl/Ibuprofen-PC (PLx Pharma)

10.8.3 Naproxcinod (NicOx)

10.8.4 Lodotra/RAYOS Horizon Pharma, SkyePharma)

10.8.5 Tofacitinib (Pfizer)

10.8.6 Ofatumumab (Genmab, GSK)

10.8.7 Mastinitib (AB Science)

10.8.8 Belimumab (GSK, Human Genome Sciences)

10.9 The Future of Pain Research

10.9.1 Advanced Drug Delivery

10.9.1.1 Delivery of Low Solubility Drugs

10.9.2 Challenges Faced by Novel Painkillers - Monoclonal Antibodies (MAbs)

10.9.3 Novel Opioid Molecules

10.10 Cannabinoids and Pain

11. Drivers and Restraints in the Worldwide Pain Relieving Drug Market, 2013-2023

11.1 STEP/SWOT Analysis of the World Pain Relieving Drug Market, 2013-2023

11.2 Social, Technological, Economic and Political Factors Affecting the Pain Relieving Drug

Market (STEP Analysis), 2013-2023

11.2.1 Social Factors Influencing the Pain Relieving Drug Market

11.2.2 Technological Factors Influencing the Pain Relieving Drug Market

11.2.3 Economic Factors Influencing the Pain Relieving Drug Market

11.2.4 Political Factors Influencing the Pain Relieving Drug Market

11.3 Market Drivers

11.4 Market Restraints

11.5 The Pain Market after the Withdrawal of COX-2 Inhibitors

11.6 Lack of Adequate Reimbursement Limits Potential of Pain Drugs

11.7 Reformulations of Existing Drugs Will Drive Market Growth

11.8 Narcotics Market Will Continue to Grow Despite Reported Concerns of Side Effects

11.9 Risk of Intestinal Bleeding Associated With Use of NSAIDs

11.10 Ageing Population

11.11 Patent Expiries Will Lead to Generic Competition

11.12 OTC Switching

11.13 Education in Pain Management is a Key Unmet Need

11.13.1 Personalised Pain Management Therapy

12. Research Interviews from Our Survey

12.1 Interview with Dr Bradley S. Galer, MD, President of Pain Group, Nuvo Research Inc.

12.1.1 Perspective on the Pain Treatment Market

12.1.2 Challenges in the Pain Treatment Market

12.1.3 Insight on the Topical Pain Relief Market

12.1.4 Thoughts on Arthritic Pain Market Developments

12.1.5 Thoughts on Key Submarkets

12.1.6 Views on Drivers and Threats

12.1.7 Treatments in the R&D Pipeline

12.1.8 Future of World Pain Treatment Market

12.2 Interview with Dr John Andrews, President and Chief Scientific Officer, NeurAxon.

12.2.1 Perspective on the Pain Treatment Market

12.2.2 Key Unmet Needs

12.2.3 Thoughts on Key Submarkets

12.2.4 Development of the Anti-Migraine Drug Market

12.2.5 Views on Drivers and Threats

12.2.6 Thoughts on National Market Opportunities

12.2.7 Treatments in the R&D Pipeline

12.2.8 Views on the Future of the Market

12.3 Interview with Dr Tuulikki Sokka, MD, PhD, Head of Rheumatology, Jyvaskyla Central Hospital, Finland.

12.3.1 On Current and Future Anti-arthritic Treatments

12.3.2 On Unmet Needs in the Anti-arthritic Sector

12.3.3 On the R&D Pipeline for Rheumatoid Arthritis

12.3.4 On Drivers of the Anti-arthritic Therapy Sector

12.3.5 On Global Prevalence of Rheumatoid Arthritis

13. Conclusions

13.1 The Pain Drug Market Will Achieve Revenue Growth from 2013

13.2 Narcotics Submarket Will Grow Despite Reported Concerns

13.3 Strong Growth Expected in Neuropathic and Cancer Pain Submarkets

13.4 Botox Approval Expected to Boost Anti-Migraine Submarket

13.5 The Anti-Arthritic Pain Drug Submarket Will Remain Strong

13.6 Leading National Markets Will Achieve Revenue Growth

13.7 The Worldwide Pain Drug Treatment Market Holds Strong Potential from 2013 to 2023

List of Tables

Table 2.1 Defining Acute and Chronic Pain

Table 3.1 World Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 3.2 World Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for

Submarkets, 2012-2017

Table 3.3 World Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for

Submarkets, 2018-2023

Table 3.4 World Pain Relieving Drug Market: Market Shares (%) by Submarkets in 2012, 2017 & 2023

Table 4.1 World Narcotic Pain Relieving Drugs Market: Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.2 Leading Narcotic Pain Relieving Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2012-2017

Table 4.3 Leading Narcotic Pain Relieving Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2018-2023

Table 4.4 World Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 4.5 World Oxycontin ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.6 World Opana ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.7 World Duragesic Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.8 World Ultram ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.9 World Zaldiar/Ixprim Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 4.10 World Other Narcotic Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.1 World Non-Narcotic Pain Relieving Drugs Market: Sales Forecast ($m), AGRs (%),

CAGRs (%), 2012-2023

Table 5.2 Leading Non-Narcotic Pain Relieving Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2012-2017

Table 5.3 Leading Non-Narcotic Pain Relieving Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2018-2023

Table 5.4 World Non-Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 5.5 Advil North American Formulations, 2013

Table 5.6 World Advil Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.7 Panadol Formulations, 2013

Table 5.8 World Panadol Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.9 World Bayer Aspirin Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.10 World Efferalgan Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.11 Tylenol Products, 2013

Table 5.12 World Tylenol Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 5.13 World Other Non-Narcotic Pain Relieving Drug Sales Forecast ($m), AGRs (%),

CAGRs (%), 2012-2023

Table 6.1 Key Drugs Indicated for Neuropathic Pain, 2013

Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2013

Table 6.3 World Neuropathic Pain Relieving Drugs Market: Sales Forecast ($m), AGRs (%),

CAGRs (%), 2012-2023

Table 6.4 Rising Prevalence of Diabetes, 2011, 2030 & 2050

Table 6.5 Leading Neuropathic Pain Relieving Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2012-2023

Table 6.6 World Neuropathic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 6.7 World Lyrica Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 6.8 World Cymbalta Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 6.9 World Lidoderm Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 6.10 World Neurontin Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 6.11 World Nucynta Franchise Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.1 World Anti-Migraine Drugs Market: Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.2 Leading Anti-Migraine Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.3 World Anti-Migraine Drug Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 7.4 World Maxalt Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.5 World Zomig Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.6 World Relpax Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.7 World Imitrex/Imigran Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.8 World Botox Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.9 World Axert Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 7.10 World Treximet Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.1 Examples of Anti-Arthritic Pain Drugs, 2013

Table 8.2 World Anti-Arthritic Drugs Market: Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.3 World Anti-Arthritic Drugs Market: Market Shares (%) of Leading Drugs in 2012, 2017 & 2023

Table 8.4 Leading Anti-Arthritic Drugs: Sales Forecasts ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.5 World Humira Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.6 World Enbrel Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.7 World Remicade Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.8 World Rituxan Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.9 World Celebrex Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.10 World Voltaren Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 8.11 World Arcoxia Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.1 Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading National Markets, 2012-2017

Table 9.2 Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading National Markets, 2018-2023

Table 9.3 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2012, 2017 & 2023

Table 9.4 US: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.5 Japan: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.6 Germany: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.7 France: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.8 UK: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGR (%), 2012-2023

Table 9.9 Italy: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.10 Spain: Pain Relieving Drugs Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.11 China: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.12 Brazil: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.13 Russia: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.14 India: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.15 Turkey: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 9.16 Rest of the World: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2012-2023

Table 10.1 R&D Pipeline for Narcotic Pain Drugs, 2013

Table 10.2 R&D Pipeline for Non-Narcotic Pain Drugs, 2013

Table 10.3 R&D Pipeline for Neuropathic Pain Drugs, 2013

Table 10.4 R&D Pipeline for Anti-Migraine Pain Drugs, 2013

Table 10.5 R&D Pipeline for Anti-Arthritic Pain Drugs, 2013

Table 11.1 STEP Analysis of the Pain Relieving Drug Market, 2013-2023

Table 11.2 SWOT Analysis of the Pain Relieving Drug Market, 2013-2023

Table 11.3 World Population Forecast, 2012-2023

List of Figures

Figure 2.1 Pain Categories

Figure 3.1 World Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 3.2 World Pain Relieving Drug Market: Market Shares (%) by Submarkets, 2012

Figure 3.3 World Pain Relieving Drug Market: Market Shares (%) by Submarkets, 2017

Figure 3.4 World Pain Relieving Drug Market: Market Shares (%) by Submarkets, 2023

Figure 4.1 World Narcotic Pain Relieving Drugs Market: Sales Forecast ($m), 2012-2023

Figure 4.2 World Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2012

Figure 4.3 World Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2017

Figure 4.4 World Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2023

Figure 4.5 World Oxycontin ER Sales Forecast ($m), 2012-2023

Figure 4.6 World Opana ER Sales Forecast ($m), 2012-2023

Figure 4.7 World Duragesic Sales Forecast ($m), 2012-2023

Figure 4.8 World Ultram ER Sales Forecast ($m), 2012-2023

Figure 4.9 World Zaldiar/Ixprim Sales Forecast ($m), 2012-2023

Figure 4.10 World Other Narcotic Drug Sales Forecast ($m), 2012-2023

Figure 5.1 World Non-Narcotic Pain Relieving Drugs Market: Sales Forecast ($m), 2012-2023

Figure 5.2 World Non-Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading

Drugs, 2012

Figure 5.3 World Non-Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading

Drugs, 2017

Figure 5.4 World Non-Narcotic Pain Relieving Drug Market: Market Shares (%) of Leading

Drugs, 2023

Figure 5.5 World Advil Sales Forecast ($m), 2012-2023

Figure 5.6 World Panadol Sales Forecast ($m), 2012-2023

Figure 5.7 World Bayer Aspirin Sales Forecast ($m), 2012-2023

Figure 5.8 World Efferalgan Sales Forecast ($m), 2012-2023

Figure 5.9 World Tylenol Sales Forecast ($m), 2012-2023

Figure 5.10 World Other Non-Narcotic Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 6.1 World Neuropathic Pain Relieving Drugs Market: Sales Forecast ($m), 2012-2023

Figure 6.2 Rising Prevalence of Diabetes, 2011, 2030 & 2050

Figure 6.3 World Neuropathic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2012

Figure 6.4 World Neuropathic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2017

Figure 6.5 World Neuropathic Pain Relieving Drug Market: Market Shares (%) of Leading Drugs, 2023

Figure 6.6 World Lyrica Sales Forecast ($m), 2012-2023

Figure 6.7 World Cymbalta Sales Forecast ($m), 2012-2023

Figure 6.8 World Lidoderm Sales Forecast ($m), 2012-2023

Figure 6.9 World Neurontin Sales Forecast ($m), 2012-2023

Figure 6.10 World Nucynta Franchise Sales Forecast ($m), 2012-2023

Figure 7.1 World Anti-Migraine Drugs Market: Sales Forecast ($m), 2012-2023

Figure 7.2 World Anti-Migraine Drug Market: Market Shares (%) of Leading Drugs, 2012

Figure 7.3 World Anti-Migraine Drug Market: Market Shares (%) of Leading Drugs, 2017

Figure 7.4 World Anti-Migraine Drug Market: Market Shares (%) of Leading Drugs, 2023

Figure 7.5 World Maxalt Sales Forecast ($m), 2012-2023

Figure 7.6 World Zomig Sales Forecast ($m), 2012-2023

Figure 7.7 World Relpax Sales Forecast ($m), 2012-2023

Figure 7.8 World Imitrex/Imigran Sales Forecast ($m), 2012-2023

Figure 7.9 World Botox Sales Forecast ($m), 2012-2023

Figure 7.10 World Axert Sales Forecast ($m), 2012-2023

Figure 7.11 World Treximet Sales Forecast ($m), 2012-2023

Figure 8.1 World Anti-Arthritic Drugs Market: Sales Forecast ($m), 2012-2023

Figure 8.2 World Anti-Arthritic Drug Market: Market Shares (%) of Leading Drugs, 2012

Figure 8.3 World Anti-Arthritic Drug Market: Market Shares (%) of Leading Drugs, 2017

Figure 8.4 World Anti-Arthritic Drug Market: Market Shares (%) of Leading Drugs, 2023

Figure 8.5 World Humira Sales Forecast ($m), 2012-2023

Figure 8.6 World Enbrel Sales Forecast ($m), 2012-2023

Figure 8.7 World Remicade Sales Forecast ($m), 2012-2023

Figure 8.8 World Rituxan Sales Forecast ($m), 2012-2023

Figure 8.9 World Celebrex Sales Forecast ($m), 2012-2023

Figure 8.10 World Voltaren Sales Forecast ($m), 2012-2023

Figure 8.11 World Arcoxia Sales Forecast ($m), 2012-2023

Figure 9.1 US, Japan & Total World: Pain Relieving Drug Sales Forecasts ($m), 2012-2023

Figure 9.2 Leading European Markets: Pain Relieving Drug Sales Forecasts ($m), 2012-2023

Figure 9.3 Leading Asian and Emerging Markets: Pain Relieving Drug Sales Forecasts ($m), 2012-2023

Figure 9.4 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2012

Figure 9.5 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2017

Figure 9.6 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2023

Figure 9.7 US: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.8 Japan: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.9 Germany: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.10 France: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.11 UK: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.12 Italy: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.13 Spain: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.14 China: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.15 Brazil: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.16 Russia: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.17 India: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.18 Turkey: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 9.19 Rest of The World: Pain Relieving Drug Sales Forecast ($m), 2012-2023

Figure 11.1 World Population Forecast, 2012-2023

Figure 11.2 World Population Aged 65 and Over: Forecast, 2012-2023

Figure 11.3 Population Aged 65 and Over in Seven Leading Developed Pain Drug Markets, 2012 & 2023

Companies Listed

AB Science

Abbott Laboratories

AcelRx Pharmaceuticals

Actavis

Acura Pharmaceuticals

Allergan

Almirall

Alpharma

ALZA Corporation

American Academy of Pain Medicine

American Council for Headache Education

Amgen

Anesiva

Aoxing Pharmaceuticals

Apotec.

Apotex.

Arcion Therapeutics

Astellas Pharma

AstraZeneca

Australian New Zealand Clinical Trials Registry (ANZCTR)

Avanir Pharmaceuticals

Bayer

BioDelivery Sciences

Biogen Idec

Biovail Corporation

Boston Millennia Partners

Bristol-Myers Squibb

Britannia Pharmaceuticals

CeNeS Pharmaceuticals

Centocor Ortho Biotech

China Aoxing

CK Life Sciences

Collegium Pharmaceutical

CoLucid Pharmaceuticals

Dainippon

Dara Biosciences

Depomed

Descartes Therapeutics

Dr. Reddy's Laboratories

Durect

Eisai

Eli Lilly

Endo Pharmaceuticals

EpiCept

Eurocept BV

European Medicines Agency (EMA)

Food and Drug Administration (FDA)

Forest Pharmaceuticals

Frazier Healthcare Ventures

Galderma

Genentech

Genmab

GlaxoSmithKline (GSK)

Grunenthal

Horizon Pharma

Human Genome Sciences

Insys Therapeutics

International Association for the Study of Pain

Ipsen

IVAX Pharmaceuticals

Janssen Pharmaceuticals

Johns Hopkins University

Johnson and Johnson (J&J)

Jyvaskyla Central Hospital

King Pharmaceuticals

Ligand Pharmaceuticals

Longitude Capital

Lundbeck

MAP Pharmaceuticals

Merck & Co.

Merck Serono

Mitsubishi Tanabe Pharma

Mundipharma

Mylan

National Cancer Institute (NCI)

National Health Service (NHS)

National Institute for Health and Clinical Excellence (NICE UK)

Nektar Therapeutics

NeurAxon

NeurogesX

Neurotune

Newron Pharmaceuticals

NicOx Pharmaceuticals

Novartis

NuPathe

Nuvo Research

Omeros

Ono Pharmaceutical

Organon

Ortho-McNeil

Pacira Pharmaceuticals

Pain Therapeutics

Paion

Paladin

Par Pharmaceuticals

Penwest

Pfizer

Pharmacia

PLx Pharma

Pozen

PriCara Pharmaceuticals

Procter & Gamble

Proteus

Purdue Pharma

QRxPharma

Ranbaxy

Ratiopharm

Rigel Pharmaceuticals

Roche

Sanofi

Schering Plough

Shire

SkyePharma

Skyline Ventures

Solvay Pharmaceuticals

Spinifex Pharmaceuticals

Stada Pharmaceuticals

Sun Pharmaceuticals

Syntaxin

Takeda

Teikoku

Teva Pharmaceutical Industries

The Arthritis Foundation

The International Diabetes Federation (IDF)

The Neuropathy Association

The World Health Organization (WHO)

UCB

University of Queensland

US Census Bureau

US Society for Neuroscience

US WorldMeds

Valeant Pharmaceuticals International

Watson Pharmaceuticals

WEX Pharmaceuticals

Wyeth (now part of Pfizer)

Xenoport

Zars Pharmaceuticals

Zenyaku Kogyo

Zogenix

To order this report:

Drug_and_Medication Industry: World Pain Relieving Drug Market 2013-2023

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

Rates

View Comments (0)